Business Context and Reporting Period
This Form 8-K reports on the 2017 Annual Meeting of Stockholders held by EyeGate Pharmaceuticals, Inc. on June 21, 2017. The filing details the voting results for four proposals submitted to security holders. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity plan amendments rather than financial performance.
Material Changes and Voting Results
Stockholders approved all four proposals presented at the Annual Meeting:
- Election of Directors: Thomas E. Hancock, Praveen Tyle, and Dr. Morton F. Goldberg were elected as Class II Directors for a three-year term. All nominees received significant majority support with votes withheld ranging from approximately 47,000 to 98,000.
- Ratification of Auditors: The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017, was ratified with 7,097,296 votes for and 139,022 votes against.
- Employee Stock Purchase Plan Amendment: Stockholders approved an amendment to increase the maximum number of shares authorized for issuance under the 2014 Employee Stock Purchase Plan by 100,000 shares.
- Equity Incentive Plan Amendment: Stockholders approved an amendment to increase the maximum number of shares authorized for issuance under the 2014 Equity Incentive Plan by 250,000 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of voting outcomes.
Important Facts for Investors to Verify
- Confirmation that the 100,000 share increase to the Employee Stock Purchase Plan and the 250,000 share increase to the Equity Incentive Plan have been formally implemented in the company's cap table.
- Verification of the new total authorized share counts for both equity plans following these amendments.
- Review of the upcoming fiscal year 2017 financial statements to be audited by the newly ratified firm, EisnerAmper LLP.